The Jackson Laboratory has developed a stable iPSC line, KOLF2.1J, with high genomic stability and wide applicability to various diseases. This cell line can be used as a reference platform for large-scale collaborative studies and accelerate human disease research.
A team of researchers from top institutions has launched the SenNet Consortium to study senescent cells, which may contribute to aging and age-related diseases. The study aims to identify potential therapies that can remove senescent cells and improve human health as we age.
A team of scientists from The Jackson Laboratory has adapted cancer therapeutic CAR-T cell therapy to eliminate SARS-CoV-2 virus pre- and post-infection in vitro. They have also developed an ACE2-bispecific-based therapy that can target all variants, including Delta and Omicron.
Researchers found radiotherapy induces consistent genomic damage through DNA deletions, which can lead to poor outcomes. Targeting error-prone DNA repair mechanisms may enhance radiotherapy efficacy.
Researchers have identified similarities between canine and human gliomas, including genetic mutations and immune system features. These findings suggest that studying dog brain tumors may provide insights into human glioma treatments, particularly in children.
The Jackson Laboratory (JAX) has announced a research affiliation with Shriners Hospitals for Children to study genetic orthopedic conditions in children. JAX scientists have also published papers on recombination and its role in meiosis and fertility, as well as the impact of microbiome diversity on skin health.
A recent study by the Glioma Longitudinal Analysis (GLASS) Consortium discovered highly variable and patient-specific genomic alterations in diffuse gliomas over time. The research team characterized initial and recurrence samples from 222 patients, revealing that gliomas do not evolve consistently under cancer therapies.
Researchers have characterized extensive structural variants in three family trios, uncovering 818,054 small insertions and deletions and 27,622 SVs per genome. Many of these variations are missed by routine sequencing technologies, revealing a vast genetic repertoire that can inform new disease associations and diagnostic methods.
Researchers have identified a link between inflammation and cancer growth in HER2-negative breast cancers, revealing anakinra as a potential treatment target. Anakinra, an existing anti-inflammatory drug, reduces gene expression of IL1b and other cytokines, improving symptoms and quality of life for some patients.
Jackson Laboratory Assistant Professor Mingyang Lu has developed a computational approach called RACIPE to capture genetic events in cellular decision-making. The algorithm could have broad impact on basic research and designing new therapeutic interventions in genomic medicine.
Researchers can now access eight new mouse models carrying genetic mutations found in patients with late-onset Alzheimer's disease. These models express variants at genetic loci associated with the disease but not yet proven to be causative, offering a significant advancement in AD research.
A team of researchers has identified 40 new subtypes of retinal ganglion cells, shedding light on the molecular differences that distinguish them. The study, published in Nature Communications, provides a detailed census of RGCs and demonstrates the importance of single-cell RNA sequencing in understanding cell type identity.
Researchers at Jackson Laboratory explore APOEε4 mutation role in Alzheimer's disease, interacting with up to 20 other implicated genes. The study uses diverse mouse populations to understand complex genetic mechanisms underlying the disease.
A new $2.2 million federal grant will fund research into genetic factors regulating ovarian reserve, which can impact fertility and reproductive lifespan. The study aims to identify gene variants contributing to ovarian reserve, offering new diagnosis and treatment avenues for fertility problems.
A $2.2 million grant will fund research into genetically controlled breaks in the external limiting membrane, which could lead to new prevention and treatment strategies for ESCS and other retinal diseases. The study aims to understand how these breaks contribute to disease progression.
Researchers identify Protein Daple as crucial for both single-cell and organ-wide directionality in hair cells of the inner ear. Without Daple, mice exhibit developmental defects in hair bundles, affecting sound wave detection and processing.
Dendritic cells known as cDC2s are crucial for robust T cell induction and antibody production in vaccination. The study found that intradermal injections may be more efficient than traditional methods, expanding the number of people who can be vaccinated during a pandemic.
The NIH has awarded Jackson Laboratory for its innovative software to improve data sharing in heart disease research. Researchers will now have access to genomic data shared by humans and animal models, enabling them to fast-track their studies.
The collaboration aims to establish a PDX Data Commons and Coordinating Center to integrate and share PDX treatment data for research. This will enhance precision in measuring drug-response and provide a clinical trial roadmap for piloting treatments.
Julia Oh has received a $2.8 million NIH grant to explore engineered probiotic treatments for skin diseases. Her research aims to harness the skin microbiome to create new therapeutics.
A multi-institutional research center has been awarded by the NIH to study ME/CFS, a debilitating disease affecting millions of Americans. The research aims to understand and develop treatments for this complex condition by analyzing patient data and microbiome changes.
A new $5.4 million grant to JAX will fund research on cognitive resilience to Alzheimer's disease. Understanding the genetic factors behind this resilience could lead to targets for treatment and prevention of Alzheimer's.
Ouyang aims to decipher RNA structure's role in post-transcriptional regulation, providing insights into health and diseases. He plans to develop a precise genomic blueprint for clinical diagnoses and prognoses, as well as new therapies for cancer and other diseases.
A five-year federal research grant will fund studies on the gut microbiome's role in MS, led by Yanjiao Zhou. The research aims to investigate how intermittent fasting alters the gut microbiome and may reduce MS symptoms.
Researchers will investigate regulatory mechanisms and biomarkers of healthy aging, aiming to understand why the immune system weakens with age. The study may lead to new treatments for age-related health issues, such as increased vulnerability to infections and cancers.
The Jackson Laboratory will investigate a new mouse model for amyotrophic lateral sclerosis (ALS) with a $3.2 million federal research grant. The study aims to link genetic mutations in the mouse models to human ALS or other neuromuscular diseases.
A research team has revealed intrinsic gene expression patterns of glioblastoma tumors, which could drive more effective treatments. The study found that tumor microenvironment cells contribute to the 'ecosystem' of hundreds of GBM tumors, influencing treatment outcomes and response to immunotherapy.
Two subsets of dendritic cells work together to activate T cells against a virus. CD141+ DCs produce viral fragments from infected CD1c+ DCs, which they then present to T cells.
A recent study has made a breakthrough in understanding the autoimmune process that leads to type 1 diabetes, finding a way to protect beta cells from destruction. By targeting the activation of B cells, researchers were able to prevent diabetes in non-obese diabetic mice.
JAX researcher Catherine Kaczorowski will receive a $2.7M federal grant to investigate the complex processes involved in both healthy aging and Alzheimer's disease through genomic studies. The goal is to identify genetic factors, mechanisms underlying normal aging, and potential targets for intervention against Alzheimer's.
Researchers at JAX will study mouse models of inherited RPE-driven disease to identify potential molecular pathways for druggable targets. Their goal is to prevent, delay onset or decrease the severity of age-related macular degeneration and other heritable retinal diseases.
JAX Professor Yijun Ruan has received a $1.05 million grant from the Human Frontier Science Program to explore the fundamental mechanics of memory and learning, as well as epilepsy. The research team will investigate how genome topology contributes to changes in gene expression that underlie these conditions.
New technologies enable basic scientists to build upon clinical genomicist work, promoting a virtuous cycle of bench-to-bedside collaboration. The researchers' recommendations prioritize data sharing, clinically relevant genes, and better data-management practices.
Researchers defined cell-type composition of cancerous cells from 11 colorectal tumors using single-cell genomics and computational techniques. The study identified two distinct subtypes of cancer-associated fibroblasts that contribute to a worse prognosis in colorectal cancer patients.
Researchers at JAX have received $2.8 million in federal grants to develop better diagnostics and treatments for triple-negative breast cancer (TNBC). The studies aim to understand the underlying mechanisms that control metastasis and identify promising therapeutic targets.
The Jackson Laboratory is developing a high-throughput approach to improve the efficiency of targeted nuclease-mediated HDR for genome editing. The goal is to significantly enhance the reliability and accuracy of CRISPR-Cas9 technology, enabling faster and more cost-effective therapeutic delivery.
Researchers found that vitamin B3 administration eliminated age-related molecular changes and provided robust protection against glaucoma. The treatment boosted metabolic reliability of aging retinal ganglion cells, keeping them healthier for longer.
The National Human Genome Research Institute awards JAX a four-year $6.7 million grant to launch a center for three-dimensional genome mapping of the human and mouse genomes as part of the ENCODE initiative.
Researchers at Jackson Laboratory have identified a newly discovered telomere maintenance mechanism that enables cancer cells to survive and thrive. The study found that most cancer cells reactivate telomerase through TERT transcription, but the exact mechanisms behind this process remained unclear until now.
The grant will accelerate the creation of high-priority mouse models for Charcot-Marie-Tooth disease and other peripheral neuropathies. Researchers aim to investigate disease mechanisms and develop treatments, which currently have no cures or effective treatments.
The NIDA grant will fund a new center combining behavioral neuroscientists, computational biologists, and geneticists to study addiction mechanisms. Researchers will analyze mouse populations with high genetic variation to identify predisposing traits, correlating them with human genomes.
The National Institutes of Health (NIH) has awarded $28.3 million to The Jackson Laboratory over five years to fund phase 2 of the Knockout Mouse Production and Phenotyping Project (KOMP2). This project aims to create targeted knockout mutations for every gene in the mouse genome, providing valuable clues to their function.
JAX researchers found a precise way to identify the kind of cell that leads to a given case of leukemia through whole-genome profiling of open chromatin. This approach may provide insight into tumor subtypes and possibly diagnostic and therapeutic benefits.
The Jackson Laboratory's Gene Expression Database (GXD) will receive $10.5 million in funding over five years to support data curation and integration, infrastructure expansion, and enhanced tools.
Researchers at Jackson Laboratory aim to develop clinical adjuvants that boost vaccine effectiveness in vulnerable populations, with a focus on elderly and immunosuppressed patients. The $3.4 million grant will support the screening of new adjuvant combinations and investigation into their mechanisms of action.
The study reveals that genetic variants can affect protein levels through post-transcriptional effects, including direct protein-protein interactions. By combining quantitative proteomics and transcriptomics, researchers can infer the proteome-wide effects of a specific genetic variant.
The Harold Alfond Foundation's charitable gift will support The Jackson Laboratory's efforts to enhance cancer diagnostics and treatment in Maine. JAX aims to provide precision cancer care using the latest genetic technologies to determine the best treatment for each patient.
Chronic fatigue syndrome (CFS) affects millions of Americans, causing profound fatigue, cognitive dysfunction, and sleep abnormalities. A new study led by Professor Derya Unutmaz aims to develop better diagnostic tools and personalized treatments for the disease.
A new approach could help women of reproductive age preserve their fertility during cancer treatment by targeting DNA damage response in oocytes. This method has shown promise in animal models and may prevent premature ovarian insufficiency and infertility.
Researchers have discovered a molecular fingerprint of some deadly cancers, including a genomic configuration called the tandem duplicator phenotype (TDP) that is enriched in triple-negative breast cancer and other types. This TDP is sensitive to cisplatin chemotherapy and can be scored using a genome-based formula.